The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis?

5024Background: The mCRPC patient population is heterogeneous, and clinical outcomes are influenced by clinical presentation and treatment history. Using the Prostate Cancer Registry (NCT02236637) database, we assessed whether the subset of mCRPC patients with metastatic (M) status at initial diagnosis represents patients with different clinical and disease characteristics in a real-life context. Methods: We report findings from the first 1323 consecutive patients in the Prostate Cancer Registry, a 3-year, prospective, observational study of the routine management of > 3000 patients with mCRPC across Europe. Results: Of the 1323 patients analyzed, 549 had distant metastases at initial diagnosis (M1, 41.5%), 526 did not (M0, 39.8%), and 248 were not evaluable (Mx, 18.7%). Conclusions: In this sample of 1323 men with mCRPC in routine practice, a higher percentage with M1 at diagnosis presented with aggressive and extended disease at mCRPC. M status at initial diagnosis may be a critical indicator of future ...